How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

731 results for

Sibutramine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients

metabolism, in excess of 14 days (i.e. sibutramine, orlistat, thyroid hormones, systemic corticosteroids and other weight loss/modifying agents) Impaired liver function, defined as ALT (alanine aminotransferase) at least 2.5 times upper limit of normal (central laboratory value measured at screening visit) Inadequately treated high blood pressure defined as Class 2 hypertension or higher (i.e. systolic blood pressure equal to or above 160 mm Hg or diastolic equal to or above 100 mm Hg) in accordance

2015 Clinical Trials

162. Study on health hazards through medicines purchased on the Internet: a cross-sectional investigation of the quality of anti-obesity medicines containing crude drugs as active ingredients. (PubMed)

and not medicines. Even though we did not analyze the constituents of all crude drugs, we found some active ingredients in the items. Sibutramine was detected in items confirmed to be supplements, including those containing Poria sclerotium and Ophiopogonis tuber. Each capsule contained ≈ 12 mg of sibutramine, which is the daily dose for anti-obesity medicines. Sibutramine is not approved for use in Japan and its sale has been suspended in Europe and the USA owing to serious adverse effects on the circulatory

Full Text available with Trip Pro

2015 BMC Complementary and Alternative Medicine

163. Randomized Controlled Trial of Preconception Interventions in Infertile Women With Polycystic Ovary Syndrome. (PubMed)

of preconception and infertility treatment at Academic Health Centers in women with infertility due to PCOS, age 18-40 y and body mass index 27-42 kg/m(2).Women were randomly assigned to receive either 16 weeks of 1) continuous oral contraceptive pills (OCPs) (ethinyl estradiol 20 mcg/1 mg norethindrone acetate) ("OCP"); 2) lifestyle modification consisting of caloric restriction with meal replacements, weight loss medication (either sibutramine, or orlistat), and increased physical activity to promote a 7

Full Text available with Trip Pro

2015 The Journal of clinical endocrinology and metabolism

164. Pediatric obesity: Causes, symptoms, prevention and treatment (PubMed)

, hypothalamic melanocortin 4 receptor, and mitochondrial uncoupling proteins, are known to affect body weight. These molecules serve as potential targets for the pharmacological manipulation of obesity. Sibutramine and orlistat are primariliy used for the treatment of adult obesity, which produces modest weight loss, of 3-8% compared to placebo. For children and obese adolescents, metformin is used in the case of insulin resistance and hyperinsulinemia. Octreotide is used for hypothalamic obesity. Bariatric

Full Text available with Trip Pro

2015 Experimental and therapeutic medicine

165. Natural drugs aren’t necessary safe. Don’t make that mistake.

with anabolic steroids. Some of these contaminated supplements were Vitamin C and magnesium tablets. They also found that nutritional supplements were adulterated with the stimulants ephedrine, caffeine, methylenedioxymethamphetamine (MDMA, “ecstasy”) and sibutramine (Meridia, a prescription-only weight loss drug). This is a problem unique to the United States. In Europe, the herbal industry is as stringently regulated as the prescription medication industry. When a person purchases an herbal remedy from

2015 KevinMD blog

166. ChemDIS: a chemical–disease inference system based on chemical–protein interactions (PubMed)

. An analysis on maleic acid and sibutramine showed that ChemDIS could be a useful tool for the identification of potential functions, pathways and diseases affected by poorly characterized chemicals.ChemDIS is an integrated chemical-disease inference system for poorly characterized chemicals with potentially affected functions and pathways for experimental validation. ChemDIS server is freely accessible at http://cwtung.kmu.edu.tw/chemdis.

Full Text available with Trip Pro

2015 Journal of Cheminformatics

167. A Single Dose Pharmacokinetic Study of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age

containing St. John's Wort is prohibited within 4 weeks before dosing. Treatment within 4 weeks of dosing with over-the-counter weight loss products or appetite suppressants (including herbal weight loss agents), or within 3 months of dosing with a prescription weight loss drug (eg, phentermine, sibutramine, orlistat) or lipid dissolving injections (eg, Lipodissolve). Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may

2015 Clinical Trials

168. Efficacy of adjunctive treatments added to olanzapine or clozapine for weight control in patients with schizophrenia: a systematic review and meta-analysis. (PubMed)

identified through searching the Cochrane Central Register of Controlled Trials, PubMed, and PsycINFO. Fourteen randomized clinical trials were included for systematic review and meta-analysis from 132 potential trials. The Comprehensive Meta-Analysis version 2 was used for meta-analysis.Difference in means and significances from meta-analyses regarding weight control by adjunctive treatments showed that topiramate, aripiprazole, or sibutramine was more effective than metformin or reboxetine. Psychiatric

Full Text available with Trip Pro

2015 TheScientificWorldJournal

169. Predicting Meaningful Outcomes to Medication and Self-Help Treatments for Binge-Eating Disorder in Primary Care: The Significance of Early Rapid Response. (PubMed)

Predicting Meaningful Outcomes to Medication and Self-Help Treatments for Binge-Eating Disorder in Primary Care: The Significance of Early Rapid Response. We examined rapid response among obese patients with binge-eating disorder (BED) in a randomized clinical trial testing antiobesity medication and self-help cognitive-behavioral therapy (shCBT), alone and in combination, in primary-care settings.One hundred four obese patients with BED were randomly assigned to 1 of 4 treatments: sibutramine (...) , placebo, shCBT + sibutramine, or shCBT + placebo. Treatments were delivered by generalist primary-care physicians and the medications were given double-blind. Independent assessments were performed by trained and monitored doctoral research clinicians monthly throughout treatment, posttreatment (4 months), and at 6- and 12-month follow-ups (i.e., 16 months after randomization). Rapid response, defined as ≥65% reduction in binge eating by the fourth treatment week, was used to predict outcomes.Rapid

Full Text available with Trip Pro

2015 Journal of Consulting and Clinical Psychology

170. Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial. (PubMed)

Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial. The Sibutramine Cardiovascular OUTcomes (SCOUT) trial showed a significantly increased relative risk of nonfatal cardiovascular events, but not mortality, in overweight and obese subjects receiving long-term sibutramine treatment with diet and exercise. We examined the relationship between early changes (both increases and decreases) in pulse rate, and the impact (...) of these changes on subsequent cardiovascular outcome events in both the placebo and sibutramine groups.9804 males and females, aged ⩾55 years, with a body mass index of 27-45 kg m(-)(2) were included in this current subanalysis of the SCOUT trial. Subjects were required to have a history of cardiovascular disease and/or type 2 diabetes mellitus with at least one cardiovascular risk factor, to assess cardiovascular outcomes. The primary outcome event (POE) was a composite of nonfatal myocardial infarction

2015 International Journal of Obesity

171. Treatment of obesity in primary care practice in the United States: a systematic review

of relevant studies and reviews were searched. Study selection Randomised controlled trials (RCTs) of weight loss interventions in adults in USA that involved counselling by a primary care provider (or in a simulated primary care setting) were eligible for inclusion. Treatments used in included studies were brief primary care provider counselling (alone or with orlistat or sibutramine) or collaborative (involved registered dietitians or nurses who supported primary care providers). Treatment duration

Full Text available with Trip Pro

2009 DARE.

172. A Proof of Principal Study of Atomoxetine for the Prevention of Vasovagal Syncope

of norepinephrine transport (NET) reuptake with sibutramine and reboxetine (NET inhibitors) prevents syncope on tilt testing by about 80%, and the investigators reported that sibutramine markedly reduced the frequency of vasovagal syncope in 7 of our most symptomatic patients. Sibutramine and reboxetine, for different reasons, are not available in Canada. However atomoxetine is available and is used to help patients with attention deficit disorder. There are no data pertaining to its hemodynamic effects

2014 Clinical Trials

173. A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. (PubMed)

A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. No long-term studies have compared centrally acting drugs for treating obesity.To compare the efficacy and safety of diethylpropion (DEP), fenproporex (FEN), mazindol (MZD), fluoxetine (FXT) and sibutramine (SIB) in promoting weight loss.A prospective, randomized, placebo (PCB)-controlled study conducted at a single academic institution.A total of 174 obese premenopausal women.Participants randomly

2014 International Journal of Obesity

174. Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease. (PubMed)

Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease. The Sibutramine Cardiovascular OUTcomes (SCOUT) trial showed a significantly increased relative risk of nonfatal cardiovascular events, but not mortality, in overweight and obese subjects receiving long-term sibutramine treatment with diet and exercise. We examined the relationship between early changes (both increases and decreases) in body weight and blood (...) . Post hoc subgroup analyses of weight change (categories) and blood pressure were performed overall and by treatment group (6-week sibutramine followed by randomized placebo or continued sibutramine). The primary outcome event (POE) was a composite of nonfatal myocardial infarction, nonfatal stroke, resuscitated cardiac arrest or cardiovascular death. Time-to-event analyses of the POE were performed using Cox regression models with factors for treatment, subgroups and interactions.During the initial

2014 International Journal of Obesity

175. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. (PubMed)

. Secondary outcomes included clinically relevant weight change, fasting glucose, hemoglobin A1c, fasting insulin, insulin resistance, cholesterol, and triglycerides.Forty trials representing 19 unique interventions were included in this meta-analysis. Metformin was the most extensively studied drug in regard to body weight, the mean difference amounting to -3.17 kg (95% CI: -4.44 to -1.90 kg) compared to placebo. Pooled effects for topiramate, sibutramine, aripiprazole, and reboxetine were also different (...) from placebo. Furthermore, metformin and rosiglitazone improved insulin resistance, while aripiprazole, metformin, and sibutramine decreased blood lipids.When nonpharmacological strategies alone are insufficient, and switching antipsychotics to relatively weight-neutral agents is not feasible, the literature supports the use of concomitant metformin as first choice among pharmacological interventions to counteract antipsychotic-induced weight gain and other metabolic adversities in schizophrenia.©

Full Text available with Trip Pro

2014 Schizophrenia bulletin

177. Processed Orange and the Glycemic Response

(oral or ocular) (e.g., Sotalol, Bisoprolol), beta-adrenergic drugs, calcium channel blocking agents (Amlodipine, Nicardipine), angiotensin converting enzyme (ACE) inhibitors (Captopril, Cilazapril), angiotensin receptor blocking agents (Valsartan), nitrates, diuretics (Chlortalidone), venlafaxine and sibutramine, decongestants or chloroquine Systolic blood pressure >150 mmHg and/or diastolic blood pressure >95 mmHg CVD including coronary artery disease, left ventricular hypertrophy, congestive

2014 Clinical Trials

178. A Prospective, Randomized, Double-blind, Placebo Controlled Study to Assess the Impact of ORMD-0801 (Insulin Capsules) on the Exogenous Insulin Requirements of Type 1 Diabetics

or immunomodulating agents History of severe or multiple allergies, or known allergy to soy or aprotinin. History of tobacco or nicotine use within 10 weeks prior to screening Patient is on a weight loss program and is not in the maintenance phase, or patient that started weight loss medication (e.g., orlistat or sibutramine) within 8 weeks prior to screening Pregnancy or breast-feeding Patient has a screening visit systolic blood pressure of ≥165 mmHg or diastolic blood pressure of ≥100 mmHg. Patient

2014 Clinical Trials

179. Whey Protein Study

(including severe depression, lithium treatment, schizophrenia, severe behavioural disorders) Vegetarians & Vegans Medication Exclusion Criteria: Orlistat (Xenical) Oral antidiabetics, insulin Rimonabant (Acomplia) Digoxin, anti-arrhythmics Sibutramine (Reductil) Tricyclic antidepressants, neuroleptics Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided

2014 Clinical Trials

180. The Effect of n-3 Fatty Acid Supplementation on Serum Levels, and Gene Expression of type2 Diabetes Patient

supplements, vitamins and herbal products at least 3 months before and throughout the intervention Exclusion Criteria: people who have used n-3 Fatty Acid Supplementation in last 3 months, having chronic renal disease , GI disease, Hepatobiliary diseases, hematological disorders, hypo- or hyperthyroidism, type 1 diabetes, treatment with orlistat or sibutramine for weight loss, pregnancy and lactation, treatment with insulin or Thiazolidinediones. Contacts and Locations Go to No Contacts or Locations

2014 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>